at://
/
app.bsky.feed.post
/
3mjfere26pc2q
sign in
All
4
Record
2
Post
1
PostEmbed
1
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Impressive! endpoints.news/revolution-m...
2mo
Revolution Medicines reported that its experimental KRAS inhibitor, called daraxonrasib, succeeded in a registrational trial for pancreatic cancer.
endpoints.news
Revolution Medicines' pancreatic cancer drug doubles survival time in Phase 3
Adam Gilbert
